Insulin Edema in a Patient With Cystic Fibrosis–Related Diabetes
نویسندگان
چکیده
Insulin edema is a rare complication of insulin therapy primarily seen with newly diagnosed or uncontrolled diabetes (1–3). Patients at risk are those who are beginning insulin treatment, underweight, or increasing their insulin dose either in the normal course of the disease or after diabetic ketoacidosis (1,4). The prevalence of insulin edema is unknown; a review of the literature revealed few case reports of insulin edema and no reports of insulin edema in a patient with cystic fibrosis–related diabetes (CFRD). This case report illustrates the effects of insulin edema in a 23-year-old female patient who was diagnosed with CFRD at the age of 16 years. The patient presented to the pediatric endocrine clinic at the age of 16 years with an HbA1c of 9.8%. She started therapy on an insulin pump, andwithin 1month, her HbA1c level fell within target range, and a lung transplant occurred in December 2007. One year later, her HbA1c increased to 11.9%, and physical exam (PE) revealed lower extremity (LE) edema to the midcalf. Three months later, her HbA1c increased to 12.5%. The patient’s pump download data revealed that insulin had only been administered for 2 nonconsecutive days before her appointment. Almost 1 year after a pump re-education session (August 2009), the patient’s HbA1c decreased to 11.8%. Pump download data revealed increased bolus intake as the patient’s appointment neared. PE revealed nonpitting LE edema. All of the potential causes of edema were considered, including cardiac abnormalities, liver impairment, and transplant medications. Furosemide was prescribed but did not resolve the edema. Six months later, the patient’s HbA1c increased to 16.5%. Consistent with prior visits, her pump download data revealed insulin delivery only on the 2 days before clinic appointment. The patient again complained of swelling in her legs and face, stating that it was worse when taking insulin. PE revealed extensive 21 LE edema up to her thigh. At that time, her treatment regimen was changed to multiple daily injections with aspart and glargine insulin pens. One month later, her HbA1c decreased to 13.4%, and her edema began to resolve with 2 1 LE edema to the midcalf. In October 2010, HbA1c decreased to 9%, and the patient reported improved compliance with her insulin pump. However, 3 months later, HbA1c increased to 12.4%. The pump download data revealed that no insulin had been delivered in the past 14 days, and no edema was noted on the PE. The patient’s edema would begin to resolve when insulin use was nonexistent or minimal and would return before follow-up appointments, coinciding with her sudden increased use of insulin. The exact cause of insulin edema is unknown, and diagnosis is made by eliminating all other causes of edema (1). It often resolves without intervention; however, a reduction in insulin dose may resolve the edema (1). Short-term diuretic therapy, salt restriction, or ephedrine has been studied and shown to be effective in correcting acute edema (1,3). Insulin edema can be difficult to diagnose with concomitant disease states and medications, but the possibility of insulin edema occurring in a patient should be considered with insulin nonadherence and whenever starting or increasing an insulin dose. KATHERINE S. O’NEAL, PHARMD, MBA, CDE BETHANY A. FRANCIS, BA MICHELLE E. CONDREN, PHARMD, AE-C, CDE LAURA J. CHALMERS, MD
منابع مشابه
Insulin Edema in Type 2 Diabetes Mellitus: A Case Report Study
Edema is a rare complication induced by insulin therapy, which is mostly developed after initiation or intensification of insulin treatment in diabetic patients. Edema can either be localized or generalized. Our patient was a 34-year-old woman with type 2 diabetes. She was under treatment with oral agents medication, but recently insulin therapy was initiated for her due to inability to control...
متن کاملOpen randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus
BACKGROUND Diabetes mellitus may be present in patients with cystic fibrosis starting in the second decade of life. The prevalence increases rapidly with increasing age. As life-expectancy increases in cystic fibrosis, cystic fibrosis related diabetes will be diagnosed more frequently in the future.Up to date, no data are available to answer the question if cystic fibrosis related diabetes shou...
متن کاملLong-Term Follow-Up in a Girl with Cystic Fibrosis and Diabetes Since the First Year of Life
Diabetes mellitus is the most common comorbidity in cystic fibrosis (CF). Recently, more attention has been paid to early glucose metabolism derangements (GMDs). The subject of this report is a female patient, affected by CF since 3 months of age. She presented with intermittent diabetes during early childhood. At the age of 10 years, oral glucose tolerance test (OGTT) was performed and showed ...
متن کاملClinical Care Guidelines for Cystic Fibrosis–Related Diabetes
C ystic fibrosis–related diabetes (CFRD) is the most common comorbidity in people with cystic fibrosis (CF), occurring in 20% of adolescents and 40–50% of adults (1). While it shares features of type 1 and type 2 diabetes, CFRD is a distinct clinical entity. It is primarily caused by insulin insufficiency, although fluctuating levels of insulin resistance related to acute and chronic illness al...
متن کاملLetter to the Editor Regarding: Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related Diabetes
As noted recently by Jones et al., hypoglycemia is common in hospitalized patients with cystic fibrosis-related diabetes (CFRD) and is associated with an increase in readmission or death [1]. Though insulin therapy has been blamed for episodes of hypoglycemia, we noted ketonemia (elevated fingerstick 3-hydroxybutyrate) in several hospitalized patients with CFRD and hypoglycemia [2]; serum gluca...
متن کامل